Sustained-release reservoir implants for intracameral drug delivery

A sustained release implant for intraocular use to treat elevated intraocular pressure, configured for intracameral or anterior vitreal administration to a patient with elevated intraocular pressure (lOP), said implant comprising a core, which is fabricated as a bundle of individual fibres comprising an antihypertensive agent, said core is surrounded by a non-biodegradable polymer which limits the rate of passage of the antihypertensive agent from the implant into the eye of said patient, wherein:

• the antihypertensive agent is selected from the group consisting of bimatoprost, latanoprost, travoprost, unoprostone, EP2/EP4 receptor agonists, timolol, betaxolol, levobetaxolol, carteolol, levobunolol, propranolol, brirnonidine, apraclonidine, epinephrine, dipivefrin, pilocarpine, Latrunculin B compound, vaptans, anecortave acetate, ethacrynic acid, cannabinoids, brinzolamide, acetazolamide and EP2 receptor agonists;
• and
• the implant provides a linear rate of release of therapeutically effective amounts of said anti-hypertensive into said eye for a period of time of between 12 days and 365 days.